Duodenal-jejunal bypass liners are superior to optimal medical management in ameliorating metabolic dysfunction: A systematic review and meta-analysis.
duodenal-jejunal bypass liner
type 2 diabetes
weight loss
Journal
Obesity reviews : an official journal of the International Association for the Study of Obesity
ISSN: 1467-789X
Titre abrégé: Obes Rev
Pays: England
ID NLM: 100897395
Informations de publication
Date de publication:
08 2023
08 2023
Historique:
revised:
12
03
2023
received:
06
07
2022
accepted:
16
04
2023
medline:
13
7
2023
pubmed:
8
5
2023
entrez:
8
5
2023
Statut:
ppublish
Résumé
This systematic review and meta-analysis evaluates metabolic and anthropometric outcomes of duodenal-jejunal bypass liners (DJBLs) compared to optimal medical management for the treatment of obesity and its associated metabolic complications. A systematic search of MEDLINE, Embase, Scopus, and Web of Science databases was conducted. Studies were reviewed and data were extracted following the PRISMA guidelines. The primary outcome was glycated hemoglobin (HbA1c) change at device explant with secondary outcomes including body mass index (BMI), weight, fasting plasma glucose (FPG), and adverse events. Twenty-eight studies met inclusion criteria evaluating a total of 1229 patients undergoing DJBL treatment. When compared to medical management, DJBLs provided superior reductions in HbA1c (mean difference, MD -0.96%; 95% CI -1.43, -0.49; p < 0.0001), FPG (MD -1.76 mmol/L; 95% CI -2.80, -0.72; p = 0.0009), BMI (MD -2.80 kg/m
Substances chimiques
Glycated Hemoglobin
0
Types de publication
Meta-Analysis
Systematic Review
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
e13572Informations de copyright
© 2023 The Authors. Obesity Reviews published by John Wiley & Sons Ltd on behalf of World Obesity Federation.
Références
Finkelstein EA, Khavjou OA, Thompson H, et al. Obesity and severe obesity forecasts through 2030. Am J Prev Med. 2012;42(6):563-570. doi:10.1016/j.amepre.2011.10.026
Ward ZJ, Bleich SN, Cradock AL, et al. Projected U.S. state-level prevalence of adult obesity and severe obesity. N Engl J Med. 2019;381(25):2440-2450. doi:10.1056/NEJMsa1909301
Twells LK, Gregory DM, Reddigan J, Midodzi WK. Current and predicted prevalence of obesity in Canada: a trend analysis. CMAJ Open. 2014;2(1):E18-E26. doi:10.9778/cmajo.20130016
Jirapinyo P, Haas AV, Thompson CC. Effect of the duodenal-Jejunal bypass liner on glycemic control in patients with type 2 diabetes with obesity: a meta-analysis with secondary analysis on weight loss and hormonal changes. Diabetes Care. 2018;41(5):1106-1115. doi:10.2337/dc17-1985
Ruban A, Ashrafian H, Teare JP. The EndoBarrier: duodenal-Jejunal bypass liner for diabetes and weight loss. Gastroenterol Res Pract. 2018;2018(101475557):7823182. doi:10.1155/2018/7823182
Ruban A, Miras AD, Glaysher MA, et al. Duodenal-jejunal bypass liner for the management of type 2 diabetes mellitus and obesity: a multicenter randomized controlled trial. Ann Surg. 2022;275(3):440-447. doi:10.1097/SLA.0000000000004980
Caiazzo R, Branche J, Raverdy V, et al. Efficacy and safety of the duodeno-jejunal bypass liner in patients with metabolic syndrome: a multicenter randomized controlled trial (ENDOMETAB). Ann Surg. 2020;272(5):696-702. doi:10.1097/SLA.0000000000004339
Glaysher MA, Ward J, Aldhwayan M, et al. The effect of a duodenal-jejunal bypass liner on lipid profile and blood concentrations of long chain polyunsaturated fatty acids. Clin Nutr (Edinburgh, Scotland). 2021;40(4):2343-2354. doi:10.1016/j.clnu.2020.10.026
Dang JT, Mocanu V, Park H, et al. Ileal microbial shifts after Roux-en-Y gastric bypass orchestrate changes in glucose metabolism through modulation of bile acids and L-cell adaptation. Sci Rep. 2021;11(1):23813. doi:10.1038/s41598-021-03396-4
de Jonge C, Fuentes S, Zoetendal EG, et al. Metabolic improvement in obese patients after duodenal-jejunal exclusion is associated with intestinal microbiota composition changes. Int J Obes (Lond). 2005;43(12):2509-2517. doi:10.1038/s41366-019-0336-x
Mocanu V, Zhang Z, Deehan EC, et al. Fecal microbial transplantation and fiber supplementation in patients with severe obesity and metabolic syndrome: a randomized double-blind, placebo-controlled phase 2 trial. Nat Med. 2021;27(7):1272-1279. doi:10.1038/s41591-021-01399-2
Rodriguez-Grunert L, Galvao Neto MP, Alamo M, Ramos AC, Baez PB, Tarnoff M. First human experience with endoscopically delivered and retrieved duodenal-jejunal bypass sleeve. Surg Obes Relat Dis. 2008;4(1):55-59. doi:10.1016/j.soard.2007.07.012
Ryder REJ, Yadagiri M, Burbridge W, et al. Duodenal-jejunal bypass liner for the treatment of type 2 diabetes and obesity: 3-year outcomes in the first National Health Service (NHS) EndoBarrier service. Diabet Med. 2022;39(7):e14827. doi:10.1111/dme.14827
Obermayer A, Tripolt NJ, Aziz F, et al. EndoBarrier TM implantation rapidly improves insulin sensitivity in obese individuals with type 2 diabetes mellitus. Biomolecules. 2021;11(4):574. doi:10.3390/biom11040574
Moher D, Liberati A, Tetzlaff J, Altman DG, The PG. Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis of observational studies in epidemiology (MOOSE) group. Jama. 2000;283(15):2008-2012. doi:10.1001/jama.283.15.2008
Haddaway NR, Collins AM, Coughlin D, Kirk S. The role of Google scholar in evidence reviews and its applicability to grey literature searching. PLoS ONE. 2015;10(9):e0138237. doi:10.1371/journal.pone.0138237
Wan X, Wang W, Liu J, Tong T. Estimating the sample mean and standard deviation from the sample size, median, range and/or interquartile range. BMC Med Res Methodol. 2014;14(1):135. doi:10.1186/1471-2288-14-135
Higgins JPT, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ (Clinical Research Ed). 2003;327(7414):557-560. doi:10.1136/bmj.327.7414.557
Slim K, Nini E, Forestier D, Kwiatkowski F, Panis Y, Chipponi J. Methodological index for non-randomized studies (minors): development and validation of a new instrument. ANZ J Surg. 2003;73(9):712-716. doi:10.1046/j.1445-2197.2003.02748.x
Khan W, Khan M, Alradwan H, Williams R, Simunovic N, Ayeni OR. Utility of intra-articular hip injections for femoroacetabular impingement: a systematic review. Orthop J Sports Med. 2015;3(9):2325967115601030. doi:10.1177/2325967115601030
Sterne JAC, Savovic J, Page MJ, et al. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ. 2019;366:l4898. doi:10.1136/bmj.l4898
Betzel B, Homan J, Aarts EO, et al. Weight reduction and improvement in diabetes by the duodenal-jejunal bypass liner: a 198 patient cohort study. Surg Endosc. 2017;31(7):2881-2891. doi:10.1007/s00464-016-5299-6
Cohen R, le Roux CW, Papamargaritis D, et al. Role of proximal gut exclusion from food on glucose homeostasis in patients with type 2 diabetes. Diab Med. 2013;30(12):1482-1486. doi:10.1111/dme.12268
Colas A, Varela M, Mraz M, et al. Influence of glucometric 'dynamical' variables on duodenal-jejunal bypass liner (DJBL) anthropometric and metabolic outcomes. Diabetes Metab Res Rev. 2020;36(4):e3287. doi:10.1002/dmrr.3287
de Moura EGH, Martins BC, Lopes GS, et al. Metabolic improvements in obese type 2 diabetes subjects implanted for 1 year with an endoscopically deployed duodenal-jejunal bypass liner. Diabetes Technol Ther. 2012;14(2):183-189. doi:10.1089/dia.2011.0152
Deutsch L, Ben Haim L, Sofer Y, Gluck N, Santo E, Fishman S. Long-term effects of proximal small bowel exclusion by duodenal-jejunal bypass liner on weight reduction and glycemic control in diabetic patients. Surg Obes Relat Dis. 2018;14(10):1561-1569. doi:10.1016/j.soard.2018.07.022
Escalona A, Pimentel F, Sharp A, et al. Weight loss and metabolic improvement in morbidly obese subjects implanted for 1 year with an endoscopic duodenal-jejunal bypass liner. Ann Surg. 2012;255(6):1080-1085. doi:10.1097/SLA.0b013e31825498c4
Forner PM, Ramacciotti T, Farey JE, Lord RV. Safety and effectiveness of an endoscopically placed duodenal-jejunal bypass device (EndoBarrier R): outcomes in 114 patients. Obes Surg. 2017;27(12):3306-3313. doi:10.1007/s11695-017-2939-4
Gersin KS, Rothstein RI, Rosenthal RJ, et al. Open-label, sham-controlled trial of an endoscopic duodenojejunal bypass liner for preoperative weight loss in bariatric surgery candidates. Gastrointest Endosc. 2010;71(6):976-982. doi:10.1016/j.gie.2009.11.051
Koehestanie P, de Jonge C, Berends FJ, Janssen IM, Bouvy ND, Greve JWM. The effect of the endoscopic duodenal-jejunal bypass liner on obesity and type 2 diabetes mellitus, a multicenter randomized controlled trial. Ann Surg. 2014;260(6):984-992. doi:10.1097/SLA.0000000000000794
Kratochvilova H, Lacinova Z, Klouckova J, et al. Neudesin in obesity and type 2 diabetes mellitus: the effect of acute fasting and weight reducing interventions. Diabetes Metab Syndr Obes. 2019;12(101515585):423-430. doi:10.2147/DMSO.S193259
Laubner K, Riedel N, Fink K, et al. Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: a case control study. Diabetes Obes Metab. 2018;20(8):1868-1877. doi:10.1111/dom.13300
McMaster JJ, Rich GG, Shanahan ER, et al. Induction of meal-related symptoms as a novel mechanism of action of the duodenal-Jejunal bypass sleeve. J Clin Gastroenterol. 2020;54(6):528-535. doi:10.1097/MCG.0000000000001353
Patel N, Mohanaruban A, Ashrafian H, et al. EndoBarrier R: a safe and effective novel treatment for obesity and type 2 diabetes? Obes Surg. 2018;28(7):1980-1989. doi:10.1007/s11695-018-3123-1
Quezada N, Munoz R, Morelli C, et al. Safety and efficacy of the endoscopic duodenal-jejunal bypass liner prototype in severe or morbidly obese subjects implanted for up to 3 years. Surg Endosc. 2018;32(1):260-267. doi:10.1007/s00464-017-5672-0
Riedel N, Laubner K, Lautenbach A, et al. Longitudinal evaluation of efficacy, safety and nutritional status during one-year treatment with the duodenal-jejunal bypass liner. Surg Obes Relat Dis. 2018;14(6):769-779. doi:10.1016/j.soard.2018.02.029
Rodriguez L, Reyes E, Fagalde P, et al. Pilot clinical study of an endoscopic, removable duodenal-jejunal bypass liner for the treatment of type 2 diabetes. Diabetes Technol Ther. 2009;11(11):725-732. doi:10.1089/dia.2009.0063
Roehlen N, Laubner K, Bettinger D, et al. Duodenal-Jejunal bypass liner (DJBL) improves cardiovascular risk biomarkers and predicted 4-year risk of major CV events in patients with type 2 diabetes and metabolic syndrome. Obes Surg. 2020;30(4):1200-1210. doi:10.1007/s11695-019-04324-2
Rohde U, Federspiel CA, Vilmann P, et al. The impact of EndoBarrier gastrointestinal liner in obese patients with normal glucose tolerance and in patients with type 2 diabetes. Diabetes Obes Metab. 2017;19(2):189-199. doi:10.1111/dom.12800
Ryder REJ, Irwin SP, Burbridge W, et al. The United Kingdom's first NHS Endobarrier service for advanced diabesity: 1-year outcomes for all 62 treated patients. BRIT J Diab. 2019;19(2):110-117. doi:10.15277/bjd.2019.226
Schouten R, Rijs CS, Bouvy ND, et al. A multicenter, randomized efficacy study of the EndoBarrier gastrointestinal liner for presurgical weight loss prior to bariatric surgery. Ann Surg. 2010;251(2):236-243. doi:10.1097/SLA.0b013e3181bdfbff
Stratmann B, Krepak Y, Schiffer E, et al. Beneficial metabolic effects of duodenal jejunal bypass liner for the treatment of adipose patients with type 2 diabetes mellitus: analysis of responders and non-responders. Horm Metab Res. 2016;48(10):630-637. doi:10.1055/s-0042-115175
Tarnoff M, Rodriguez L, Escalona A, et al. Open label, prospective, randomized controlled trial of an endoscopic duodenal-jejunal bypass sleeve versus low calorie diet for pre-operative weight loss in bariatric surgery. Surg Endosc. 2009;23(3):650-656. doi:10.1007/s00464-008-0125-4
Vilarrasa N, de Gordejuela AGR, Casajoana A, et al. Endobarrier in grade I obese patients with Long-standing type 2 diabetes: role of gastrointestinal hormones in glucose metabolism. Obes Surg. 2017;27(3):569-577. doi:10.1007/s11695-016-2311-0
de Jonge C, Rensen SS, Verdam FJ, et al. Endoscopic duodenal-jejunal bypass liner rapidly improves type 2 diabetes. Obes Surg. 2013;23(9):1354-1360. doi:10.1007/s11695-013-0921-3
Betzel B, Cooiman MI, Aarts EO, et al. Clinical follow-up on weight loss, glycemic control, and safety aspects of 24 months of duodenal-jejunal bypass liner implantation. Surg Endosc. 2020;34(1):209-215. doi:10.1007/s00464-019-06752-8
Kavalkova P, Mraz M, Trachta P, et al. Endocrine effects of duodenal-jejunal exclusion in obese patients with type 2 diabetes mellitus. J Endocrinol. 2016;231(1):11-22. doi:10.1530/JOE-16-0206
van Rijn S, Roebroek YGM, de Jonge C, Greve JWM, Bouvy ND. Effect of the EndoBarrier device: a 4-year follow-up of a multicenter randomized clinical trial. Obes Surg. 2019;29(4):1117-1121. doi:10.1007/s11695-018-03659-6
Clavien PA, Sanabria JR, Strasberg SM. Proposed classification of complications of surgery with examples of utility in cholecystectomy. Surgery. 1992;111(5):518-526.
Still CD, Benotti P, Wood GC, et al. Outcomes of preoperative weight loss in high-risk patients undergoing gastric bypass surgery. Arch Surg. 2007;142(10):994; discussion 9-998. doi:10.1001/archsurg.142.10.994
Sun Y, Liu B, Smith JK, et al. Association of preoperative body weight and weight loss with risk of death after bariatric surgery. JAMA Netw Open. 2020;3(5):e204803. doi:10.1001/jamanetworkopen.2020.4803
Hart A, Goffredo P, Carroll R, et al. Optimizing bariatric surgery outcomes: the impact of preoperative elevated hemoglobin A1c levels on composite perioperative outcome measures. Surg Endosc. 2021;35(8):4618-4623. doi:10.1007/s00464-020-07887-9
Verhoeff K, Mocanu V, Dang J, et al. Five years of MBSAQIP data: characteristics, outcomes, and trends for patients with super-obesity. Obes Surg. 2022;32(2):406-415. doi:10.1007/s11695-021-05786-z
Robert EJ, Ryder MY, Burbridge W, et al. Duodenal-jejunal bypass liner for treatment ofT2DM and obesity: 4-year outcomes in the first National Health Service (NHS) EndoBarrierservice. Brit J Diab. 2022;22(2):82-86. doi:10.15277/bjd.2022.351
Sharples AJ, Mahawar K. Systematic review and meta-analysis of randomised controlled trials comparing long-term outcomes of Roux-En-Y gastric bypass and sleeve gastrectomy. Obes Surg. 2020;30(2):664-672. doi:10.1007/s11695-019-04235-2
Shoar S, Saber AA. Long-term and midterm outcomes of laparoscopic sleeve gastrectomy versus Roux-en-Y gastric bypass: a systematic review and meta-analysis of comparative studies. Surg Obes Relat Dis. 2017;13(2):170-180. doi:10.1016/j.soard.2016.08.011
Leventi E, Gunthert SJ, Stier C, Staikov P, Stein J, Farrag K. Is early reimplantation of the duodenal-jejunal bypass liner viable? Obes Surg. 2019;29(5):1690-1693. doi:10.1007/s11695-019-03758-y
Koehestanie P, Betzel B, Aarts EO, Janssen IMC, Wahab P, Berends FJ. Is reimplantation of the duodenal-jejunal bypass liner feasible? Surg Obes Relat Dis. 2015;11(5):1099-1104. doi:10.1016/j.soard.2015.01.016
Rubino F, Forgione A, Cummings DE, et al. The mechanism of diabetes control after gastrointestinal bypass surgery reveals a role of the proximal small intestine in the pathophysiology of type 2 diabetes. Ann Surg. 2006;244(5):741-749. doi:10.1097/01.sla.0000224726.61448.1b
Jahansouz C, Staley C, Bernlohr DA, Sadowsky MJ, Khoruts A, Ikramuddin S. Sleeve gastrectomy drives persistent shifts in the gut microbiome. Surg Obes Relat Dis. 2017;13(6):916-924. doi:10.1016/j.soard.2017.01.003
Wallenius V, Dirinck E, Fandriks L, Maleckas A, le Roux CW, Thorell A. Glycemic control after sleeve gastrectomy and Roux-En-Y gastric bypass in obese subjects with type 2 diabetes mellitus. Obes Surg. 2018;28(6):1461-1472. doi:10.1007/s11695-017-3061-3
Anderin C, Gustafsson UO, Heijbel N, Thorell A. Weight loss before bariatric surgery and postoperative complications: data from the Scandinavian obesity registry (SOReg). Ann Surg. 2015;261(5):909-913. doi:10.1097/SLA.0000000000000839
Mocanu V, Marcil G, Dang JT, Birch DW, Switzer NJ, Karmali S. Preoperative weight loss is linked to improved mortality and leaks following elective bariatric surgery: an analysis of 548,597 patients from 2015-2018. Surg Obes Relat Dis. 2021;17(11):1846-1853. doi:10.1016/j.soard.2021.06.021
de Boer H, Keizers R, Jansen M, Verschoor L, Ruineman-Koerts J. Glycaemic control without weight gain in insulin requiring type 2 diabetes: 1-year results of the GAME regimen. Diabetes Obes Metab. 2006;8(5):517-523. doi:10.1111/j.1463-1326.2005.00537.x